✦ LIBER ✦

Breast-conserving treatment with or without radiotherapy for ductal carcinoma in situ (DCIS): ten-year results of European Organisation for Research and Treatment of Cancer (EORTC) randomized phase III trial 10853

✍ Scribed by N. Bijker; Meijnen; J. Bogaerts; J.L. Peterse

Book ID: 118624509
Publisher: Elsevier Science
Year: 2006
Tongue: English
Weight: 142 KB
Volume: 4
Category: Article
ISSN: 1359-6349
DOI: 10.1016/s1359-6349(06)80229-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Radiotherapy in breast-conserving treatm

Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: first results of the EORTC randomised phase III trial 10853

✍ Jean-Pierre Julien; Nina Bijker; Ian S Fentiman; Johannes L Peterse; Vincenzo De 📂 Article 📅 2000 🏛 The Lancet 🌐 English ⚖ 93 KB

Radiotherapy in breast-conserving treatm

Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: first results of the EORTC randomised phase III trial 10853

✍ J.P Julien; N Bijker; I.S Fentiman; V Delledonne; P Rouanet; A Avril; R Sylveste 📂 Article 📅 2001 🏛 Elsevier Science 🌐 French ⚖ 21 KB

217 Adjuvant Radiotherapy After Breast-c

217 Adjuvant Radiotherapy After Breast-conserving Surgery for Ductal Carcinoma in Situ – Fifteen-year Results of the EORTC Randomized Phase III Trial 10853

✍ M. Donker; S. Litiére; G. Werutsky; J.P. Julien; I.S. Fentiman; R. Agresti; P. R 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 59 KB

Interferon-α-2a with or without 13-cis r

Interferon-α-2a with or without 13-cis retinoic acid in patients with progressive, measurable metastatic renal cell carcinoma : Results of a randomized Phase II study (European Organization for Research and Treatment of Cancer Study 30951)

✍ Sophie D. Fosså; Gerald H. J. Mickisch; Pieter H. M. De Mulder; Simon Horenblas; 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 130 KB

## Background: In patients with metastatic renal cell carcinoma (mrcc), interferon-alpha (ifn) monotherapy leads to response rates of 5-15%, dependent on the selection of patients. in 1995, preclinical and clinical data indicated an improvement of these results if ifn was combined with 13-cis retin

Randomized phase II/III trial of interfe

Randomized phase II/III trial of interferon alfa-2a with and without 13-cis-retinoic acid in patients with progressive metastatic renal cell carcinoma: The European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group (EORTC 30951): Aass N, De Mulder PHM, Mickisch GHJ, Mulders P, van Oosterom AT, van Poppel H, Fossa SD, de Prijck L, Sylvester RJ, Department of Clinical Cancer Research, The Norwegian Radium Hospital, Oslo, Norway

✍ Robert Flanigan 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 42 KB